Clinician competence in treating patients of various racial and ethnic backgrounds and the critical need for greater inclusion of diverse populations in trials investigating the pathophysiology and treatment of AD are underscored.
The safety and efficacy of once-daily abrocitinib for up to 16 weeks in reducing the signs and symptoms of moderate to severe atopic dermatitis (AD) was evaluated.
Patients with chronic hand eczema treated with oral alitretinoin who had been unresponsive to potent or super-potent topical corticosteroids were studied.
The efficacy and safety of baricitinib in a phase 3 trial of adults with atopic dermatitis who did not respond adequately or were intolerant of topical therapy was evaluated.
Exposure to antibiotics in utero and during the first year of life is associated with an increased risk for atopic dermatitis, with the correlation partially attenuated after adjustment for familial factors.
Short-term exposure to air pollution as a result of wildfire may be associated with increased health care use among patients with atopic dermatitis and itch.
